Treatment outcomes of germ cell tumors of ovary: Single institutional study

Sumedha Gargy (Rajendra Institute of Medical Sciences, Ranchi)
Rohit Kumar Jha (Rajendra Institute of Medical Sciences, Ranchi)
Ajit Kumar Kushwaha (Rajendra Institute of Medical Sciences)
Mukunda Kumar (All India Institute of Medical Sciences, Patna)

Abstract


5% of all ovarian tumours are accounted to germ cell tumours (GCT’s). Affecting mostly young women, the highest incidence is seen in second and third decade of life. They are highly malignant but chemosensitive and more curable than their epithelial counterparts. Treating these tumors with effective surgery and combination chemotherapy survival rates have dramatically improved in recent decades.

 

We present our experience of ovarian germ cell tumours in the

Department of Surgical Oncology, Rajendra Institute of Medical Sciences (RIMS), Ranchi with special emphasis on treatment outcomes. A retrospective review of hospital medical records of patients with ovarian germ cell tumours diagnosed and treated at RIMS from June 2019 to August 2020, was performed. Clinical profile and treatment outcome of patients were recorded. A total of 19 patients met criteria. The median age at diagnosis was 20 years (range 11–42 years) and all had good performance status. All except two patients underwent surgery, 70.6% and 29.4% in upfront and interval debulking surgery (IDS) setting respectively.  Fertility preserving surgery was done in 75% patients in the primary surgery group and 60% undergoing IDS.  83.3% patients received BEP as adjuvant chemotherapy whereas 80% as neo-adjuvant chemotherapy.

Majority (31.5%) patients had dysgerminoma as final histology, followed by mixed histology(26.3%), yolk sac tumour (15.7%), immature teratoma (15.7%) and choriocarcinoma (10.5%)

 

47.3% patients were in Stage I at the time of diagnosis. 78.9%  patients were alive without disease, 10.5% recurred,  and 10.5% were lost to follow up.

 


Keywords


germ cell tumour, dysgerminoma, BEP, fertility sparing surgery, yolk sac tumour

Full Text:

PDF

References


[1]Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Junco GD, Saul PB, et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer 1985;56:2756–61.

[2]Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman

[3]WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985;56:243–8.

[4]Gershenson BDM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. Am Soc Clin Oncol 2016;6:270–5.

[5]Brewer BM, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 2017;17:2670–5.

[6]Kanazawa K, Suzuki T, Sakumoto K.Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission. Am J Clin Oncol 2000;23:244–8.

[7].

[8]Tangir J, Zelterman D, MaW, et al. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.Obstet Gynecol 2003;101:251–7.

[9]Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long term outcome after multimodality treatment. J Clin Oncol. 2006;24:4862-4866.

[10]Downey J, McKinney M (1992) The psychiatric status of women presenting for infertility evaluation. Am J Orthop 62:196–198

[11]Zanetta G, Bonazzi C, Cantu M, Binidagger S, Locatelli A, Bratina

[12]G, Mangioni C (2001) Survival and reproductive function after

[13]treatment of malignant germ cell ovarian tumors. J Clin Oncol

[14](4):1015–1020

[15]Zhang N, Chen R, Hua K, Zhang Y (2017) A retrospective study of reproductive

[16]outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in

[17]malignant ovarian germ cell tumors and sex cord-stromal tumors. Journal of Ovarian Research (2017) 10:52

[18]Turkmen O, Karalok A, Basaran D, Kimyon G (2017) Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. Journal of Adolescent and Adult Oncology. DOI: 10.1089/jayao.2016.0086

[19]Maheshwari A, Gupta S, Parikh PM, Tongaonkar HB (2004)

[20]Malignant germ cell tumor ovary—experience at Tata Memorial

[21]Hospital. Indian J Med Paediatr Oncol 25(1):43

[22]Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA,

[23]Edwards CL, Silva EG,Wharton JT (1990) Treatment of malignant

[24]germ cell tumors of the ovary with bleomycin, etoposide and cisplatin.

[25]J Clin Oncol 8(4):715–720

[26]De Wit R, Roberts JT et al (2001) Equivalence of three or four

[27]cycles of bleomycin, etoposide and cisplatin combination therapy

[28]and of a 3 or 5 day schedule in good prognosis germ cell cancer: a

[29]randomized study of the European Organization for Research and

[30]Treatment of Cancer Genitourinary Tract Cancer Cooperative

[31]Group and the Medical Research Council. J Clin Oncol 19(6):

[32]–1640

[33]Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long term

[34]follow up of a phase III study of three versus four cycles of

[35]bleomycin, etoposide and cisplatin in favourable prognosis germ

[36]cell tumors: the Indian University experience. J Clin Oncol 16(2):

[37]–706

[38]Talukdar S, Kumar S, Bhatla N , Mathur S, Thulkar S, Kumar L. Neo-adjuvant chemotherapy in the treatment of advanced malignant7germ cell tumors of ovary. Gynecologic Oncology 132 (2014) 28–32

[39]Culine S, Lhomme C, Kattan J, Michel G, Duvillard P, Droz JP

[40](1997) Cisplatin based chemotherapy in the management of germ

[41]cell tumors of the ovary: the Institut Gustave Roussy Experience.

[42]Gynecol Oncol 64(1):160–165

[43]Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994;55:S62–72.

[44]Weinstein D, Polishuk WZ. The role of wedge resection of

[45]the ovary as a cause for mechanical sterility. Surg Gynecol

[46]Obstet 1975;141:417–8.

[47]Perrin LC, LowJ, Nicklin JLWardBG, Crandon AJ (1999) Fertility

[48]and ovarian function after conservative surgery for germ cell tumors

[49]of the ovary. Aust N Z J Obstet Gynecol 39(2):243–245

[50]Ezzat A, Raja M, Bakri Y, Subhi J,MemonM, Schwartz P, Stuart R

[51](1999) Malignant ovarian germ cell tumors: a survival and prognostic

[52]analysis. Acta Oncol 38(4):455–460

[53]Brewer M, Gerhenson DM, Herzog CE Mitchell MF, Silva

[54]EG, Wharton JT (1999) Outcomes and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17(9):2670–2675

[55]Park J, Kim D, Suh D, Kim J, Kim Y(2015) Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors; Gynecol Oncol (2015), http://dx.doi.org/10.1016/j.ygyno.2015.03.054

[56]

[57]Weinberg L, Lurain J, Singh D, Schink J, Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecologic Oncology 121 (2011) 285–289.

[58]Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018 Oct;219(4):385.e1-385.e7. doi: 10.1016/j.ajog.2018.07.021. Epub 2018 Aug 4. PMID: 30086295.

[59]Patterson DM, Murugaesu N, Holden L, et al. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer 2008;18:43–50.

[60]Park J Y, Kim D Y, Suh D S,et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol 2017;145:513–8.



DOI: https://doi.org/10.30564/jor.v3i1.2705

Refbacks

  • There are currently no refbacks.
Copyright © 2021 Sumedha Gargy, Rohit Kumar Jha, Ajit Kumar Kushwaha, Mukunda Kumar Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.